secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001193125-22-299375
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx CMO Patrick Yeramian moves to part-time, salary reduced to $214K; successor search ongoing
--------------------------------------------------------------------------------

- CMO Patrick Yeramian's working hours reduced to 20 per week as of Dec 1, 2022.
- Base salary adjusted to $214,000 annually from prior rate (not disclosed).
- Company expects Yeramian to transition into retirement; no definitive date set.
- Full-time successor search initiated as part of management succession process.
- Yeramian's reduced schedule not the result of any disagreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312522299375/0001193125-22-299375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312522299375/d356648d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-299375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer